- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05303402
면역억제된 성인을 대상으로 COVID-19 백신 추가 접종의 안전성과 면역원성을 평가하기 위한 3상 임상 시험.
SARS-CoV-2에 대한 재조합 단백질 RBD 융합 이종이량체 후보(PHH-1V)를 사용한 추가 용량 백신 접종의 면역원성과 안전성을 평가하기 위한 3상, 오픈 라벨, 단일 암, 다중 센터, 임상 -COVID-19에 대해 백신을 접종한 기존 면역억제 상태
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19
연구 개요
상세 설명
This is a phase IIb/III, open label, single arm, multi-center clinical trial that aims to determine safety, reactogenicity, tolerability and immunogenicity of additional vaccination with a recombinant protein receptor binding domain (RBD) fusion heterodimer candidate against SARS-CoV-2 developed by HIPRA (PHH-1V) in individuals with pre-existing immunosuppressive conditions. In this phase III study, approximately 400 eligible individuals who have received primary vaccination against COVID-19 with 3 doses of mRNA vaccine (or 2 doses plus a documented history of COVID) last dose being administered at least 91 days before day 0 will be included. Individuals recruited in Turkey which received a primary vaccination regimen using a combination of Coronavac and Comirnaty will be allowed to be included. A maximum of 50% of Individuals with history of COVID-19 disease will be allowed to be included if diagnosed at least 91 days prior, passed 30 days from hospital discharge prior to inclusion and provided they are no suffering from long covid (Post-acute COVID-19 syndrome). All participants will receive a single dose of PHH-1V on Day 0 and will be observed for 15 minutes, except for those participants reporting previous mild allergy reactions to vaccination will be observed for 30 minutes.
All participants will be provided with a paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited adverse events will be reported through Day 28. SAEs, AESI and MAAE will be reported during all the study.
On-site follow-up visits will be performed on Days 14, 91, 182 and 365.
연구 유형
등록 (실제)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 08916
- Hospital Germans Trias i Pujol
-
Barcelona, Barcelona, 스페인, 08036
- Hospital Clínic de Barcelona
-
-
Girona
-
Girona, Girona, 스페인, 17001
- Hospital Josep Trueta
-
-
-
-
Ankara
-
Ankara, Ankara, 터키 (Türkiye), 06230
- Hacettepe University Medical Faculty Hospitals
-
Ankara, Ankara, 터키 (Türkiye), 06620
- Ankara University Medical Faculty Hospitals
-
-
Istanbul
-
Istanbul, Istanbul, 터키 (Türkiye), 34010
- Koc University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 1 Male, female or transgender, ≥ 18 years old at Day 0.
- 2 Provide inform consent form
- 3 Participant who has: 3 doses of mRNA vaccines / 2 doses of mRNA vaccines and previous COVID-19 infection / 2 doses of Coronavac and 1 Comirnaty, or, 1 Coronavac and 2 Comirnaty
- 4 Participant who has: HIV infection with CD4 Tcells counts <400 / Primary antibody deficiency disorders / Kidney disease on dialysis / Kidney transplant at least >1 year / Auto Immune Disease (AID) in treatment with rituximab
- 5 For a female of childbearing potential, to have a negative pregnancy test at Day 0
- Use of any of these contraception:
- Female: hormonal contraception, intrauterine device, vasectomized partner, sexual abstinence, condom.
- Male: Vasectomized participant, sexual abstinence, condom.
Exclusion Criteria:
- 6 History of anaphylaxis to any prior vaccine
- 7 Participants has received or plans to receive live attenuated vaccines, other not live vaccines, or Vaxzevria or Janssen vaccines.
- 8 Pregnant or breast-feeding at Day 0.
- 9 A confirmed COVID-19 diagnose <90 days prior to vaccination day 0.
- 10 A clinically significant acute illness or fever at screening or 48h before day 0.
- 11 Participant had a surgery requiring hospitalisation and has not received the hospital discharge.
- 12 Participant has an ongoing severe and non-stable psychiatric condition
- 13 Participant has a problematic or risky use of substances including alcohol
- 14 Participant has a bleeding disorder that contraindicates intramuscular injection
- 15 Participant suffering from post-acute COVID-19 syndrome / long COVID
- 16 Participant received any immunotherapy to prevent/treat COVID-19 in the last 90 days
- 17 Participant is already participating in another research involving drug, biologics or device
- 18 Participant has donated ≥450 ml of blood products within 12 weeks before screening
- 19 Participant has any medical condition and/or finding that in the investigator opinion might increase participant risk, interfere with the study or impair interpretation of study data.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Experimental: COVID-19 Vaccine HIPRA 40 mcg/dose
Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose. |
COVID-19 Vaccine HIPRA, 40 mcg/dose |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Immunogenicity against Omicron, Beta, Delta at Day 0 and Day 14
기간: Day 0 and Day 14
|
Changes in neutralising antibodies measured by pseudovirus (or live virus for the HIV cohort*) neutralization against Omicron, Beta and Delta any other relevant Variants of Concern (VOC) in the epidemiologic moment, at Baseline and at Day 14 after administration of HIPRA's vaccine (PHH-1V). |
Day 0 and Day 14
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Immunogenicity against Omicron, Beta, Delta at Day 91, Day 182 and Day 365
기간: Day 91, Day 182 and Day 365
|
1. To determine and compare the changes of the immunogenicity measured by pseudovirus (or live virus for the HIV cohort) neutralization against Omicron, Beta and Delta and any other relevant Variants of Concern (VOC) in the epidemiologic moment at Days, 91, 182 and 365, after administration of HIPRA's vaccine (PHH-1V). |
Day 91, Day 182 and Day 365
|
|
Total antibodies
기간: Day 0, Day 14, Day 91, Day 182, Day 365
|
To evaluate the immunogenicity measured by means of total antibody against Receptor Binding Domain of the Spike protein of SARS-CoV-2 quantification, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and at Days 14, 91, 182 and 365 after administration of HIPRA's vaccine (PHH-1V). |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
Safety and tolerability of the booster vaccine
기간: Day 0, Day 14, Day 91, Day 182, Day 365
|
To assess the safety and tolerability of PHH-1V as an additional dose in adult individuals with pre-existing immunosuppressive conditions |
Day 0, Day 14, Day 91, Day 182, Day 365
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of SARS-CoV-2 infections
기간: Day 0, Day 14, Day 91, Day 182, Day 365
|
Number of participants with SARS-CoV-2 infections ≥14 days after PHH-1V administration. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
Number of SARS-CoV-2 severe infections (Severe cases are considered as any episode of COVID-19 requiring ≥ 24hrs of hospitalization.)
기간: Day 0, Day 14, Day 91, Day 182, Day 365
|
Number of COVID-19 severe infections ≥14 days after PHH-1V administration. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
Celular immunity
기간: Day 0, Day 14, Day 91, Day 182, Day 365
|
Antibody IgG subclasses titre usage and avidity of humoral immunity at Baseline and Days 14, 91, 182 and 365. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
T-cell cellullar immunity
기간: Day 0, Day 14, Day 91, Day 182, Day 365
|
T-cell mediated phenotype polyclonality with potential cross-reactivity capacity and gene-expression profiles against the SARS-CoV-2 Spike & RBD proteins at Baseline and at Days 14, 91, 182 and 365 in a subset of 50% of participants. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
공동 작업자 및 조사자
협력자
수사관
- 연구 책임자: Teresa Prat, Hipra Scientific, S.L.U
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HIPRA-HH-4
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .